Wall Street Analysts Are Bullish on Top Healthcare Picks

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Akebia Therapeutics (AKBAResearch Report) and Establishment Labs Holdings (ESTAResearch Report) with bullish sentiments.

Akebia Therapeutics (AKBA)

Akebia Therapeutics received a Buy rating and a $7.00 price target from Needham analyst Serge Belanger today. The company’s shares closed last Tuesday at $2.87.

According to TipRanks.com, Belanger is a 3-star analyst with an average return of 5.1% and a 45.8% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Clarus Therapeutics Holdings, Amphastar Pharmaceuticals, and Collegium Pharmaceutical.

Currently, the analyst consensus on Akebia Therapeutics is a Moderate Buy with an average price target of $5.25, which is an 82.9% upside from current levels. In a report issued on October 29, H.C. Wainwright also maintained a Buy rating on the stock with a $6.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Establishment Labs Holdings (ESTA)

BTIG analyst Marie Thibault reiterated a Buy rating on Establishment Labs Holdings today and set a price target of $95.00. The company’s shares closed last Tuesday at $72.23.

According to TipRanks.com, Thibault is a 5-star analyst with an average return of 42.4% and a 57.9% success rate. Thibault covers the Healthcare sector, focusing on stocks such as Irhythm Technologies, Edwards Lifesciences, and Boston Scientific.

Establishment Labs Holdings has an analyst consensus of Moderate Buy, with a price target consensus of $92.50.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on AKBA: